Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Walleye Capital's NBIX Position: Q3 2026 in Review
Walleye Capital increased its Neurocrine Biosciences (NBIX) stake by 116% in Q3 2026, buying an estimated $329K and bringing the position to 3,822 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4034.
Walleye Capital first reported a position in NBIX in Q3 2019 and has held it in 19 quarters since. The position peaked at $12.8M in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Walleye Capital held 3,822 shares of Neurocrine Biosciences worth $542K as of Q3 2026.
- Walleye Capital bought 2,049 Neurocrine Biosciences shares in Q3 2026, an estimated $329K.
- Neurocrine Biosciences made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4034 holding.
- Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 19 quarters since.
- Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.